OneSource Specialty Pharma Q3 miss, FY28 guidance intact

A sharp sell-off after the December quarter

OneSource Specialty Pharma Ltd. shares fell sharply after the company reported a weak set of results for the December 2025 quarter (Q3 FY26). The stock slid as much as about 18% in intraday trade, touching around ₹1,164 on the BSE, which market reports also described as a 52-week low. Separate coverage said the stock closed down 18.75% at ₹1,164. Another market update placed the stock at ₹1,187.50 on the NSE at 12:15 PM on January 27, 2026, down 17.10% from the previous close.

The trigger across reports was operational, not structural: delays in customer approvals in Canada, which affected when the company could recognise revenue. Semaglutide, a key product mentioned repeatedly in coverage, was the centre of those delays. Management also linked the delays to a prolonged transition from the MSA (Master Service Agreement) phase to the CSA (Commercial Supply Agreement) phase, which pushed out commercial supply timelines.

What the company reported for Q3 FY26

OneSource reported a net loss of ₹47 crore for Q3 FY26, reversing from a profit of ₹67 crore in the corresponding quarter last year, according to the coverage provided. Revenue for the quarter was reported at ₹290.3 crore, a 26% decline year-on-year. EBITDA for the quarter was reported at ₹17.3 crore, alongside a 3,018 basis point contraction in EBITDA margin compared with the previous year.

Some reports in the material also referenced a broader loss range of “₹47-88 crore”, but the consistent figure repeated in multiple snippets was ₹47 crore. The company’s own explanation, repeated across write-ups, was that the quarter was subdued mainly because customer approvals in Canada took longer than expected.

Why Canada approvals delayed revenue recognition

The company attributed the quarterly pressure largely to delays in customer approvals in Canada, which impacted the timing of revenue recognition. In the provided text, semaglutide was the product most often linked to those delays. Coverage noted that regulatory approvals for semaglutide were delayed in Canada, and that this directly affected sales recognition and margins during Q3.

The company also said these delays extended the MSA-to-CSA transition timeline. In practical terms, that meant a slower move from service work under earlier agreements to commercial supply under a CSA, delaying when volumes could be recognised as revenue in the quarter. Management commentary in the coverage described the quarter as “subdued” for this reason.

Market reaction: price, levels, and short-term performance

The immediate market response was steep. Reports noted an intraday fall of about 18% to around ₹1,164 on the BSE, with some describing that level as a 52-week low. Another line item said the stock fell 18.75% to close at ₹1,164.

Separately, one market snapshot cited a “recent” OneSource share price of about ₹1,247.60 and said it underperformed its sector by 5.20% over the past day. It also stated the stock declined 13.98% over five days and 3.61% over the past month, while another update put the price at ₹1,245.60, down 5.59% over the past day. These figures indicate the weakness was not limited to a single session, though the largest move was linked to the Q3 results.

Q4 sequential recovery as India semaglutide launch begins

The same material also points to a sequential recovery after the India semaglutide launch. Management commentary stated that semaglutide was launched only at the end of the quarter once the patent expired, so its contribution during that quarter was “minimal”, with a bigger contribution expected “this quarter and beyond.”

On the Q4 update in the text, management said: “our revenues today at INR 4,282 million.” Normalised, that is ₹428.2 crore. It said this reflected 47% sequential growth, “driven across all our service offerings supported by India Semaglutide commercial launch towards the end of the quarter.” On a full-year basis, the company reported INR 14,216 million, which normalises to ₹1,421.6 crore, and said this was a 2% decline year-on-year, reflecting the softer previous quarter due to delayed semaglutide approvals in Canada.

Dr Reddy’s link and what OneSource told exchanges

Dr Reddy’s Laboratories (DRL) is referenced through OneSource’s role as a manufacturing partner. In a separate exchange filing quoted in the material, OneSource Specialty Pharma said the development would have “no material impact” on its operations.

The company added it remains committed to its “long-standing valuable partnership with DRL,” but also said it has enough demand for the product from other customers, including for Canada, and that its capacities are “fully committed.” This statement is important context because it signals that, at least in the company’s description, customer concentration or a single relationship is not the only driver of capacity utilisation.

FY28 guidance reiterated, despite quarterly pressure

Despite the Q3 setback, the provided material repeatedly notes that management reaffirmed FY28 guidance. Guidance cited in the text includes:

• FY28 top line of US$100 million with a 40% EBITDA margin (as stated in management commentary).
• A separate reference to sticking to FY28 guidance of ₹40,000 crore revenue and 40% margin.
• A leverage objective targeting net debt to EBITDA below 1.5x.

The text also includes an additional line stating FY28 “organic revenue of $100 million,” which “could rise to $100 million including the proposed acquisition.” That statement appears internally inconsistent as written (same number repeated with and without acquisition), so it is presented here exactly as provided without interpretation.

Key numbers mentioned across the provided material

What to watch next

Based on the material, the near-term monitorable remains the pace of customer and regulatory approvals in Canada, especially for semaglutide-linked programs that affected Q3 revenue recognition. The company has also pointed to a ramp in semaglutide contribution after it was launched in India towards the end of the quarter, implying subsequent quarters should reflect more of the commercial impact.

Investors will also track how the MSA-to-CSA transition progresses, since management directly linked that transition timeline to the quarter’s operating performance. And with FY28 guidance reiterated, future updates are likely to be judged against the company’s stated revenue, margin, and leverage targets.

Conclusion

OneSource Specialty Pharma’s Q3 FY26 results were weighed down by Canada approval delays that affected semaglutide-related revenue recognition, triggering an 18% stock drop to around ₹1,164. The company has highlighted a Q4 sequential revenue rebound to ₹428.2 crore, while reiterating FY28 targets on revenue, margins, and leverage. The next set of updates will be closely tied to the timing of approvals in Canada and the scale-up of semaglutide contribution after the India launch.